

Amendments to the Claims:

Claims 1-20 (Canceled)

21. (Original) A pharmaceutical composition comprising human insulin-like growth factor 1 (IGF-I) and a buffer, wherein said buffer consists substantially of succinate at a concentration of about 10 mM to about 40 mM and a counterion.

22. (Original) The composition of claim 21, wherein said counterion is selected from the group consisting of sodium, potassium, ammonium, and said IGF-I.

23. (Original) The composition of claim 21, wherein the concentration of succinate is about 10 mM to about 30 mM.

24. (Original) The composition of claim 23, wherein the concentration of succinate is about 10 mM to about 20 mM.

25. (Original) The composition of claim 24, wherein the concentration of succinate is about 10 mM.

26. (Original) The composition of claim 21, wherein said composition has a pH of about 4.0 to about 7.0.

27. (Original) The composition of claim 26, wherein said pH is about 4.6 to about 6.6.

28. (Original) The composition of claim 27, wherein said pH is about 6.0.

29. (Previously presented) The composition of claim 21, further comprising a sufficient concentration of a tonicifying agent such that the composition is isotonic.

30. (Original) The composition of claim 29, wherein said tonicifying agent is sodium chloride.

31. (Original) The composition of claim 21, wherein said human IGF-I is recombinant human IGF-I.

32. (Original) The composition of claim 31, wherein said composition has a pH of about 6.0, the concentration of said succinate is about 10 mM, and the composition further comprises about 140 mM sodium chloride.

33. (Original) The pharmaceutical composition of claim 21, wherein said composition is a liquid.

34. (Original) The pharmaceutical composition of claim 21, wherein said composition is lyophilized.

Claims 35-44 (Canceled)

45. (Previously presented) A sterile injectable pharmaceutical composition comprising human insulin-like growth factor I (IGF-I) or a biologically active variant thereof and a buffer, wherein said buffer consists substantially of succinate at a concentration of 7 mM to 45 mM and a counterion, wherein said variant is a polypeptide having IGF-I activity and at least 70% sequence identity to human IGF-I.

46. (Previously presented) The composition of claim 45, wherein said composition has a pH of about 6.0, the concentration of said succinate is about 10 mM, and the composition further comprises about 140 mM sodium chloride.

Claims 47-52 (Canceled)